Title:

Tetrabenazine in treatment of hyperkinetic movement disorders

- An observational study

Authors:

Rita Miguel1, Marcelo D Mendonça1,2, Raquel Barbosa1, Filipa Ladeira1, Tânia Lampreia1, José Vale3, Paulo Bugalho1,2

Affiliations:

1. Neurology Department, Hospital Egas Moniz – Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal

2. CEDOC, Nova Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal

3. Department of Neurology, Hospital Beatriz Ângelo, Loures, Portugal.

Supplementary Material

Figure S1. Maximum reached daily dose and respective titration time for each diagnostic category.



Legend:

Abbreviations: HD, Huntington disease. TS, tardive syndrome. OM, oromandibular dyskinesia. mo, months.

Values are expressed in mg and months.

1. Visit pre-TBZ onset and *n* patients included in each diagnostic category (total *n* = 108).
2. Time spent (mo) to reach maximum TBZ dose (median).
3. Maximum daily TBZ dose (median).

Figure S2. Threshold exposure time and dose for eliciting AEs for each diagnostic category.



Legend:

Abbreviations: AE, adverse events. HD, Huntington disease. TS, tardive syndrome. mo, months. w/, with.

Values are expressed in mg and months.

1. *n* patients who developed AE (total *n* = 52).

2. Minimal threshold TBZ exposure time for eliciting AE.

3. Minimal threshold dose for eliciting AE.

Figure S3. Threshold exposure time and dose for eliciting each type of AE.



Legend:

Abbreviations: AE, adverse events. TBZ, tetrabenazine. mo, months.

Values are expressed in mg and months.

1. *n* of AEs occurrences (total *n* = 56 events).

2. Minimal TBZ exposure time for eliciting AEs.

3. Minimal threshold dose for eliciting AEs.